분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-09-02 01:47:38 , Hit : 2471
 Engineered Viruses Selectively Kill Cancer Cells

The experimental therapy could ultimately serve as a seek-and-destroy treatment for metastatic cancer.

Wednesday, August 31, 2011
By Alla Katsnelson

A single injection of a virus that has been genetically engineered to kill cancer cells can reliably infect tumors and leave healthy tissue unharmed, according to an early stage trial of 23 patients with metastatic cancers. The findings help lay the groundwork for a new type of cancer medicine using cancer-killing viruses.

Researchers injected different doses of the virus into patients with different types of metastatic cancers. After eight to 10 days, they biopsied tumor tissue from each patient and found that the virus was replicating itself in the tumors of seven of the eight patients who had received the highest dose, with no serious side effects. Several weeks after the injection, tumors in about half of the patients seemed to stop growing, and shrunk in one patient. The study is published today in the journal Nature.

While the study is not the first to test a cancer-killing viral therapy, it is the first to thoroughly document the behavior of the virus in patients' biopsy tissue. The results confirm that viruses can be used to selectively target these cells.  

One reason tumors can grow unchecked is that they suppress the immune system. However, this also makes tumor cells more susceptible to viruses, which replicate inside the infected cell until it bursts. Physicians have known for more than a century that viral infection slows tumor growth, and in recent years they've used molecular biology techniques to reëngineer more effective cancer-killing viruses.

Most such viruses now in trials are injected directly into the tumor. But what researchers really need is a therapy that could be injected into the bloodstream and seek out metastasized cancer cells throughout the body, says David Kirn, chief executive officer at Jennerex, the San Francisco-based biotech company that funded the study.

To develop JX-594, the therapy in the new study, researchers at Jennerex started with a strain of vaccinia virus, which is adept at evading the immune system. (It was also used in the smallpox vaccine.) They then armed it with a gene encoding a protein called GM-CSF, which triggers an immune attack against cancer cells. They also added a second gene for beta-galactosidase, a marker protein with which they could track the virus's replication.

The effect, says Kirn, was "a product that destroys tumors by multiple, complementary mechanisms."

Researchers still don't know how well the virus will combat cancer. Such early trials "are not supposed to determine efficacy, but obviously, everyone is looking," says Samuel Rabkin, a virologist at Massachusetts General Hospital in Boston. Rabkin was not involved in the study. Patients whose cancers seemed to stabilize weren't necessarily the ones in which the researchers found the virus replicating, he notes. "It is actually one of the large questions in the field—is the therapeutic effect directly related to the amount of virus replication in the tumor?"

Another concern is that if patients get more than one dose, the body might get better at fighting off the virus, which could disarm the therapy, says Nori Kasahara, a gene therapy researcher at the University of California, Los Angeles. "We just don't know how long-lasting the therapeutic benefit will be," he says. "If the immune system fights off the virus, then the tumor might just come back." Kasahara also did not participate in the research.

Jennerex is already testing the therapy in larger trials. It recently completed a trial in liver cancer that significantly improved patients' survival rates, Kirn says.

The current trial's results don't just bode well for JX-594, he says, but for the field of cancer-killing viruses overall. "We can now engineer a variety of different therapeutic products into this viral backbone."








867   Turning T-cells into Cancer Killers  이성욱 2011/08/12 2557
866   Next Generation: Hundreds of Cell-Analyses at Once  이성욱 2011/08/12 2152
865   New Treatment Option for Advanced Prostate Cancer  이성욱 2011/08/16 2613
864   Cancer’s Secrets Come Into Sharper Focus  이성욱 2011/08/17 2190
863   How Caffeine Fights Cancer  이성욱 2011/08/17 2165
862   Bacteria Kamikazes  이성욱 2011/08/17 2702
861   Murdoch researchers attempt to thwart hep C virus  이성욱 2011/08/19 3802
860   Toxic antibodies blitz tumours  이성욱 2011/08/25 2231
859   Gene Therapy for Immune Disorder Lasts Nine Years, Two New Studies Show  이성욱 2011/08/25 2505
858   An RNA Switch for Stem Cells  이성욱 2011/08/31 2463
  Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2471
856   Genetic circuit kills cancer cells using unique microRNAs  이성욱 2011/09/08 4970
855   Researchers Successfully Perform First Injection of Cultured Red Blood Cells in Human Donor  이성욱 2011/09/08 2378
854   Breast-cancer gene keeps DNA under wraps  이성욱 2011/09/10 2298
853   Haploid Stem Cells  이성욱 2011/09/10 2623
852   Obscure Organelle in Stem Cells and Cancer  이성욱 2011/09/13 2397
851   UK Duo Generates Haploid Mouse Stem Cells  이성욱 2011/09/14 2438
850   Can a Form of HIV Actually Cure Cancer?  이성욱 2011/09/17 2388
849   Mammoth blood proteins could be used in major surgery  이성욱 2011/09/20 3175
848   Ribosomes in Control  이성욱 2011/09/20 2650

[이전 10개] [1].. 21 [22][23][24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2023 Zeroboard / skin by ROBIN